Johnson & Johnson (NYSE:JNJ ) UBS MedTech, Tools and Genomics Summit Conference Call August 15, 2023 2:00 PM ET Company Participants Celine Martin - Group Chairman Jasmina Brooks – President, Biose...

Renewed uncertainty in relation to Johnson & Johnson's talc lawsuit settlement led to a brief and temporary selloff in JNJ stock. What was Mr. Market thinking? It looks like a "once and for all" re...

The $40 billion exchange offer for shares of Kenvue expires Friday but brokerage firms want retail investors to make their instructions before then

Two weeks ago, Fitch downgraded the U.S. credit rating from AAA to AA+. This matched the downgrade issued by Standard & Poor's (S&P) in 2011.

Kenvue is set to make its debut in the S&P 500 index, a move confirmed by S&P Dow Jones Indices following the impending completion of Johnson and Johnson's exchange offer for Kenvue stock. The incl...

Johnson & Johnson said on Thursday the U.S. Food and Drug Administration had approved its antibody-based therapy for patients with a difficult-to-treat type of blood cancer.

Holders of odd lots under 100 shares should come out ahead after J&J splits off its Kenvue unit.

The Johnson & Johnson spinoff is the consumer health company that makes Listerine and Tylenol.

Kenvue Inc., maker of Tylenol, Benadryl and other household names in health-care products, is joining the S&P 500, index provider S&P Dow Jones Indices said late Wednesday.

Earlier this year, Johnson & Johnson made an $8.9 billion offer to plaintiffs to settle its talc liabilities. A federal judge recently put those plans into doubt by rejecting the company's efforts ...